DC Field | Value | Language |
dc.contributor.author | Mazur, Ecaterina | |
dc.contributor.author | Schmid, Martin | |
dc.contributor.author | Uncu, Livia | |
dc.date.accessioned | 2020-11-10T07:35:38Z | |
dc.date.available | 2020-11-10T07:35:38Z | |
dc.date.issued | 2020-10 | |
dc.identifier.uri | http://repository.usmf.md/handle/20.500.12710/12768 | |
dc.identifier.uri | https://stiinta.usmf.md/ro/manifestari-stiintifice/zilele-universitatii | |
dc.description | State University of Medicine and Pharmacy "Nicolae Testemiteanu" Chișinău, Republic of Moldova, Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină și Farmacie „Nicolae Testemițanu” din Republica Moldova, Ziua internațională a științei pentru pace și dezvoltare | en_US |
dc.description.abstract | Introduction. Nowadays, the number of new fixed-dose combinations (FDCs) is rising
significantly. FDC is a medicine that includes two or more active
pharmaceutical ingredients (APIs) combined in a single dasage
form. Therefore, compatibility determination between APIs in fixed-dose
combinations is an indispensable step in the elaboration. To investigate
the compatibility of the components of a formulation, techniques, such as
X-ray diffraction, FT-IR spectroscopy, high-performance liquid
chromatography (HPLC) and thermal analysis (especially differential
scanning calorimetry - DSC) are used. The present study is based HPLC
High-performance liquid chromatography provides information on
possible interactions between APIs and their related interaction products. Purpose. The purpose of the present study was to investigate the compatibility of
potassium orotate in combination with spironolactone by the HPLC
method. Material and methods. The detection was carried out using Liquid Chromatograph Agilent 1100
equipped with autosampler, UV-VIS detector, applying mobile phase,
which consists of acetonitrile and phosphate buffer solution (pH=4.0)
ratio in 1:49 and 1:1, at flow rates 1 and 1.5 mL/min, injection volume
20 μL. The study was made on a RP-18 reversed column (250mm long
by 4 mm internal diameter, particle size 5μm) and at an isocratic elution
method. The APIs (potassium orotate and spironolactone) were provided
by Sigma Aldrich, USA.
Results. Due to developed method both separation and simultaneous qualitative
and quantitative determination of APIs in the mechanical mixture were
carried out, using HPLC. Spironolactone: retention time 6.9 min,
concentration 98.1% (±0.21); potassium orotate: retention time 3.06
min, concentration 91.67% (±0.15). There were just well-separated
symmetrical peaks of APIs and no additional peak in the
chromatograms. Conclusions. There is compatibility between APIs. Further studies will be performed
by other methods (DSC, FT-IF Spectrometry) to confirm the obtained
result. Acknowledgment. We thank the coordinators of the CEEPUS program, especially the
“Teaching and learning Bioanalysis” network, for the possibility of
accessing mobility CIII-RO-0010-14-1920 and the opportunity to
execute works within the Laboratory of Pharmaceutical Chemistry,
Faculty of Pharmacy, University of Graz, Austria. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Universitatea de Stat de Medicină şi Farmacie "Nicolae Testemiţanu" | en_US |
dc.subject | HPLC | en_US |
dc.subject | combination | en_US |
dc.subject | potassium orotate | en_US |
dc.subject | spironolactone | en_US |
dc.title | Compatibility determination of potassium orotate with spironolactone by high-performance liquid chromatography | en_US |
dc.type | Other | en_US |
Appears in Collections: | Culegere de postere
|